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Peritoneal metastasis, which often arises in patients with advanced gastric cancer, is well known as a miserable and ill-fated disease.
Once peritoneal metastasis is formed, it is extremely diﬃcult to defeat. We advocated EIPL (extensive intraoperative peritoneal
lavage)asausefulandpracticaladjuvantsurgicaltechniqueforthosegastriccancerpatientswhoarelikelytosuﬀerfromperitoneal
recurrence. In this paper, we review the eﬀect of EIPL therapy on prevention of peritoneal recurrence on patients with peritoneal
free cancer cells without overt peritoneal metastasis (CY+/P−) through the prospective randomized study, and we veriﬁed its
potential as an optimal and standard prophylactic therapeutic strategy for peritoneal recurrence.
1.Introduction
Signiﬁcant advances in surgical technique and perioperative
management have dramatically improved the survival of
patients with advanced gastric cancer; nevertheless, peri-
toneal metastasis is still the most common cause of tumor
progression, and the prognosis of those patients with peri-
tonealrecurrenceremainsextremelypoor[1–5].Themedian
s u r v i v a lt i m e( M S T )o fs u c hp a t i e n t si sr e p o r t e dt ob e3 –
6 months [6], and a standard regimen against peritoneal
metastasis of gastric cancer has not yet been established [7–
10].
In patients with serosal invasion, about half develop
peritoneal recurrence and die of this disease during the ﬁrst
2 years of followup, even if curative resection is performed
[11, 12]. Further, it has been reported that the survival
time of patients with cytology-positive peritoneal lavage
ﬂuid and without macroscopic peritoneal dissemination
(CY+/P−) of gastric cancer was almost the same as that of
patients with overt peritoneal metastasis [13], and the 5-
year survival rate of patients with CY+/P− is only 2% [14].
Onceperitonealmetastasisdevelops,itisquiteimpossiblefor
patients to survive. The results of several randomized clinical
trials which have been published before on perioperative
intraperitoneal chemotherapy for patients with CY+/P−
or peritoneal metastasis have not shown any signiﬁcant
demonstrations of improvement in survival as compared
with surgery alone, especially in patients with peritoneal
metastasis [3, 8, 15–18].
It is already generally accepted that peritoneal metastasis
is completed by the implantation of peritoneal free cancer
cells exfoliated from serosa-invasive tumors. Consequently,
it is considered important to prevent peritoneal metastasis
before the ﬁxation and progression of free cancer cells on the
peritoneum of patients with advanced gastric cancer. This
is because the presence of intraperitoneal free cancer cells
without macroscopic dissemination could possibly mean
a condition where the implantation of cancer cells on
the peritoneal wall has not yet occurred. The situation of
CY+/P− might be the last opportunity for surgeons to
undertake surgical intervention to rescue such patients, and
therefore, a reliable and appropriate standard prophylactic
treatment needs to be established to prevent CY+/P− gastric
cancer developing into peritoneal metastasis.2 Journal of Oncology
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Figure 1: Schema of “limiting dilution method.” This method is expected to lead to a logarithmic reduction of numerous cancer cells to
zero.
From this point of view, we have been advocating
the adoption of “extensive intraoperative peritoneal lavage”
(EIPL) as a useful intraoperative technique for an adjuvant
therapy to avoid the implantation of cancer cells on the
intraperitoneal wall after a potentially curative resection,
combined with intraperitoneal chemotherapy (EIPL-IPC).
EIPL is very simple and can be performed anywhere and
anytime. Also, it has quite an amazing power of reducing
the number of intraperitoneal free cancer cells eﬃciently
to potentially zero, analyzed by a detection system of
cancer cells using real-time reverse transcriptase-polymerase
chain reaction (RT-PCR), and intraperitoneal chemotherapy
subsequent to EIPL could play an important role in erad-
icating any remaining cancer cells. We have conﬁrmed the
clinical eﬀectiveness of EIPL by ultrarapid quantitative RT-
PCR protocol. Quite a few intraperitoneal free cancer cells
could be detected in the washing lavage ﬂuid after 6 to 8
washes. Finally, our recent prospective randomized control
study clearly revealed that EIPL-IPC therapy signiﬁcantly
improved the 5-year survival of advanced gastric cancer
patients with CY+/P− [19].
In this article, we reviewed the eﬃcacy and advantage of
our new adjuvant intraoperative method to reduce the peri-
toneal recurrence, and clariﬁed the feasibility and validity of
adopting this method as the standard prophylactic strategy
for the prevention of peritoneal metastasis in advanced
gastric cancer patients.
2.ConventionalTreatmentof
CY+ GastricCancer
To date, many studies on positive intraperitoneal free cancer
cells (CY+) in patients with advanced gastric cancer without
overt peritoneal metastasis have been conducted to assess
whether CY+ could be a predictive factor. Although most
of the studies succeeded in showing the validity of CY+
as a reliable predictive factor, there are not yet any reports
concerning drastic and eﬀective therapies for patients with
CY+ [20–27]. As mentioned already, the simple existence of
free cancer cells in the peritoneal cavity is apparently dif-
ferent from that of peritoneal dissemination; moreover, the
status of CY+/P− includes the condition where peritoneal
metastasishasnotyetoccurred.So,wehavebeenfocusingon
devising a beneﬁcial method that could improve the survival
of CY+ patients surgically.
3. EIPL(ExtensiveIntraoperative
Peritoneal Lavage)
We have proposed that EIPL is a quite formidable method
for reducing the number of intraperitoneal free cancer
cells to potentially zero, just like the so-called “limiting
dilution” approach [28]. Brieﬂy, the peritoneal cavity is
extensively stirred and washed after the potentially curative
operation, which is followed by the complete aspiration of
the ﬂuid. This procedure is done 10 times using 1L of
physiological saline. 10 washes of a 1:10 dilution result in
just 1 cancerous cell from 1010 cells in the abdominal cavity
(Figure 1). Furthermore, suﬃcient stirring and washing of
the abdominal cavity would remove the cancer cells which
merely adhere to the peritoneum. EIPL was performed in
ﬁve cases of serosa-invasive gastric cancer with CY+/P−,a n d
its eﬃcacy was evaluated by the ultrarapid quantitative RT-
P C Rp r o t o c o l ,w h i c hm a d ei tp o s s i b l et od e t e c tm R N Ao f
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Figure 2:Changesinnumbersofintraperitoneal freecancer cellsin
ﬁve gastric cancer patients with CY+ treated by EIPL therapy. The
numbers of free cancer cells in 100mL of samples from the lavage
ﬂuid using 1 liter of saline were measured by ulra-rapid RT-PCR.
The free cancer cells were serially diluted by 6 to 8 liters of saline
and disappeared in washing ﬂuid after that.
the procedure in only about 70 minutes. Sequential washing
of intraperitoneal free cancer cells of 3.8 × 105 ± 1.4 ×
105/100mL of lavage decreased the number to 2.8 ± 1.5c e l l s
by 6 to 8 washes. Free cancer cells were not detected in the
ﬂuid after that (Figure 2). On the other hand, 2.8 × 104 ±
4.5 × 104 of intraperitoneal free cancer cells still remained
in 100mL of the lavage when not treated with EIPL. Our
preliminary subset analysis based on 22 consecutive patients
with CY+/P− who underwent curative surgical treatment
for advanced gastric cancer, and who were followed up for
2 years or until death, has shown a statistically signiﬁcant
improvement of a 2-year survival rate when treated with
EIPL as compared with when not treated with EIPL [29].
4. ClinicalAdoption of EIPL-IPCTherapy
Based on our pioneering study, we have advocated EIPL-
IPC (intraperitoneal chemotherapy) therapy. After the EIPL
treatment, cisplatin (CDDP) is administrated into the
abdominal cavity at a dose of 100mg/body and the solution
is drained 1 hour after the injection. In this way, even if only
a few cancer cells were to remain, these cells might ﬁnd it
diﬃcult to survive and/or to disseminate due to the eﬀects of
IPC.
EIPL-IPC
IPC
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Figure 3:Thesurvivalcurvesforthe88patientsstratiﬁedaccording
to the treatments. ∗By log-rank test.
To clarify the distinct survival eﬀects of EIPL-IPC
therapy, we designed a prospective randomized multicenter
trial for advanced gastric cancer patients with CY+/P−.
A total of 88 gastric cancer patients with CY+/P− from
1522 patients with advanced gastric cancer at multicenters
were enrolled in this study, and were randomly allocated to
three groups: surgery alone group, surgery plus intraperi-
toneal chemotherapy (IPC) group, and surgery plus EIPL
and IPC (EIPL-IPC) group. Peritoneal lavage for the surgery
alone group and the IPC group was done with 3 liters
of saline (1 liter, three times) before the closure of the
abdominal wall or IPC, respectively.
Theoverall5-yearsurvivalrateofpatientswithEIPL-IPC
was 43.8%, and this data was signiﬁcantly higher than that
of the IPC group (4.6%, P<0.0001) and the surgery alone
group (0%, P<0.0001), as shown in Figure 3.
Among various recurrent patterns, the EIPL-IPC group
had a signiﬁcantly lower incidence of peritoneal recurrence
than either of the other groups. Univariate and multivariate
analyses clearly revealed that EIPL was the most signiﬁcant
impact factor.
The results of this study far exceeded our expectations
and showed a remarkably better prognosis than previous
studiesongastriccancerpatientswithCY+/P−.Forexample,
a study on the median survival time (MST) of 91 patients
with CY+/P− who had potentially curative operations stated
survival to be only 386 days [30], and the 5-year overall
survival rate has been 13% [31]. In our study, the surgery
alone group as well as the IPC group also showed similar
results to the reports just cited. Surprisingly, however, in
the EIPL-IPC group the overall 5-year survival rate and
MST were 42.1% and 35 months, respectively, remarkably
signiﬁcant improvement of both survival and MST. These
results were convincing and are promising enough to serve4 Journal of Oncology
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Figure 4: A practical and optimal treatment protocol for advanced gastric cancer. D2 operation: gastrectomy with dissection of group 1 and
2 lymph node [37], N(+): positive lymph node metastasis through operation, N(−): no evidence of lymph node metastasis, PCR: real-time
reverse transcriptase-polymerase chain reaction, EIPL: extensive intraoperative peritoneal lavage, IPC: intraperitoneal chemotherapy.
as a solid basis on which to build strong conﬁdence in and
high expectations for employing the EIPL-IPC therapy.
5. Further Application of EIPL Therapy
5.1. Application to CY−/P− Gastric Cancer. Despite neither
the apparent existence of abdominal free cancer cells nor
overt peritoneal metastasis, approximately half of patients
with serosa-involved gastric cancer developed peritoneal
recurrence after curative operations [27]. In addition, some
nonserosa-involved gastric cancers advance to peritoneal
recurrence, even though a curative operation has been
performed [5, 32–34]. We elucidated the mechanisms of
peritoneal recurrence after curative operations for patients
with nonserosa-involved gastric cancer.
CEA and CK20 mRNA in the peritoneal lavage samples
from 63 patients with nonserosa-involved gastric cancer
which were obtained just after laparotomy and after lymph
node dissection were examined by an ultrarapid quantitative
RT-PCR system [28]. In the peritoneal lavage samples from
nonserosa-involved cases after lymph node dissection, CEA
or CA20 mRNA were detected in 16 of 63 patients (25.4%)
despite no detection of either CEA or CA20 mRNA just
after laparotomy. These were not evident in the mucosal (M)
tumor, but were detected in three (14.3%), six (46.2%), and
seven (53.8%) patients with submucosal (SM), muscularis
propria (MP), and subserosal (SS) tumors, respectively.
These data suggested the existence of free cancer cells
in the peritoneal cavity after lymph node dissection with
non-serosa-involved gastric cancer patients. Moreover, our
previous study on 1272 gastric cancer patients revealed
that 1/257 cases (0.4%) of SM and 6/136 cases (4.4%)
of MP developed peritoneal recurrences after potentially
curative resections [34]. Among them, 86% of the patients
had lymph node metastasis and/or lymphatic invasion. Our
results demonstrated that lymph node dissection would be
a main factor for spreading viable free cancer cells into the
peritoneal cavity. Thus, we came to an assurance that lymph
node dissection itself is a cause of peritoneal dissemination,
seeding viable cancer cells from the lymphatic vessels to
the abdominal cavity. As there should be a low risk of the
completion of peritoneal metastasis in such cases with non-
serosal-involved gastric cancer, EIPL therapy will demon-
strate its eﬀectiveness to the maximum on the prevention of
peritoneal recurrences after curative operations.
5.2. Application to Other Abdominal Organ Cancers. We ap-
plied EIPL therapy to the miserable disease of pancreatic
cancer, where peritoneal recurrence is frequently found and
yieldsahighmortalityrate[35].EIPLtherapywasperformed
consecutively on 15 patients of 39 patients with invasive
ductal adenocarcinoma of the pancreas who underwent
curative surgical treatment. The peritoneal recurrence rate
of the EIPL group was signiﬁcantly lower than that of the
non-EIPL group (6.7% versus 45.8%, P = 0.013) and
the EIPL therapy was the independent negative risk factor
for peritoneal recurrence. On the basis of such attractive
data, EIPL therapy is considered to be applicable to various
abdominal cancers which are likely to seed in abdominal
cavities.
6. Proposal of EIPL Therapy as a Standard
Therapeutic Strategy for Prevention of
Peritoneal Recurrence
Lymphaticandperitonealmetastasisiswellknowntobehigh
in advanced gastric cancer while hematogenous metastasis
is relatively low [1, 36, 37]. Above all, peritoneal metastasis
is the most common cause of tumor progression and death
even if curative surgery is performed [1–5]. Once peritoneal
metastasis is formed, it becomes extremely diﬃcult for
patients to survive through to a cure, though the survival
time has become somewhat longer by excellent meansJournal of Oncology 5
including intravenous and/or intraperitoneal chemotherapy.
Several studies have suggested that chemotherapy could
possibly result in much better prognosis than would be
expected from aggressive surgery for gastric cancer patients
with CY+/P−, just like patients with peritoneal metastasis
[20, 21, 38, 39]. On the other hand, there is a report which
has demonstrated that radical surgery as well as adjuvant
chemotherapy should be performed for CY+/P− patients in
cases of no lymph node metastasis [40]. This demonstrates
that appropriate standard regimens for patients who are
likely to progress toward peritoneal metastasis, including
CY+/P− patients, has not yet been established.
As already mentioned, the situation of CY+/P− means
the condition where the implantation of free cancer cells
derived from the primary tumor has not yet occurred.
We suppose there should be apparent diﬀerences between
the conditions of CY+/P− and peritoneal metastasis which
would require diﬀerent management strategy. Therefore, it
is considered reasonable and relevant to focus on devising
some eﬀective surgical measures to prevent peritoneal recur-
rence, accompanied by appropriate and respectable radical
resection. Although the Dutch report has described the high
postoperative morbidity and mortality after gastrectomy
with D2 lymph node dissection [41], radical resections with
D2 lymphadenectomy appear to be feasible and safe for
patients in Japan [20, 21, 38, 39]. In our study, operative
morbidity and mortality were 1.5% and 0.5%, respectively.
These results show that potential beneﬁts of D2 operations
would outweigh the risk of morbidity and mortality after
the radical operation. Complete extirpation of gastric cancer
with a suﬃcient resection margin from the tumor and
removal of metastatic lymph nodes is the only measure that
could bring the hope of cure for patients with gastric cancer
[1, 36, 37, 42, 43], therefore, advanced gastric cancer should
be treated with radical resection even if it is accompanied by
CY+/P− because our novel EIPL-IPC regimen would have
the power to cancel the CY+ condition.
Lastly, we strongly advocate the adoption of the new
treatment protocol for advanced gastric cancer as shown in
Figure 4. In case of positive lymph node metastasis through
operation or positive molecular detections of CEA and CA20
mRNA in the lavage ﬂuid after lymph node dissection, EIPL
is performed even for the patients with non-serosa-involved
cancer. Except for overt peritoneal metastasis, all patients
with serosa-involved cancer undergo EIPL in principle and
IPC therapy is added to the patients with CY+ or PCR (+)
in the lavage ﬂuid just after laparotomy. After the proper
tumor resection and lymphadenectomy, EIPL (or EIPL-
IPC) therapy serves an extremely important role for gastric
cancer patients with high peritoneal recurrence risk such as
serosal invasion and lymph node metastasis. The innovative
EIPL-IPC therapy is very practical and its theoretical basis
creates high expectations as to the eﬀects of cytoreduction,
potentially to zero. Furthermore, EIPL therapy is simple, not
time-consuming, inexpensive, and it is not curtailed by place
or time, so it can easily be performed anytime, anywhere.
Also, it does not require the use of any special techniques or
devices.Inaddition,apointworthyofspecialmentionisthat
EIPL itself only has minimal risk for patients.
7. Conclusion
In conclusion, we reviewed clinical studies concerning EIPL
therapy, and very favorable results convinced us to advocate
EIPL therapy as an optimal treatment protocol for advanced
gastric cancer patients. It is our fervent wish that EIPL
therapy be adopted as the standard prophylactic strategy for
peritoneal recurrence.
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